-
2024-516048-24-00
4
2019-06-19
CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-509576-42-00
5
2019-02-21
Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
-
2024-511204-16-00
5
2019-01-23
Metastatic breast cancer
-
2023-506921-12-00
5
2018-12-27
ER+/HER2- Breast Cancer
-
2024-513206-65-00
5
2018-08-10
resected squamous cell carcinoma of head and neck
-
2024-512470-10-00
11
2018-02-02
End-stage Renal disease
-
2024-517489-41-00
5
2017-03-27
High-risk stage III colon cancer
-
2024-518741-21-00
4
2014-12-23
colon cancer
-
2024-514904-14-00
4
2014-10-08
Patients with metastatic or unresectable locally advanced malignancies
-
2024-516996-34-00
5
2012-04-12
oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
-
2023-509322-22-00
4
2025-11-26
localized colon cancer
-
2023-510559-41-00
4
2025-01-02
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
-
2023-503298-39-00
5
2024-06-13
Metastatic Non-Small Cell Lung Cancer (mNSCLC)
-
2023-505846-24-00
4
2024-04-08
acute myeloid leukemia
-
2023-506696-10-00
5
2024-06-18
Non-Small Cell Lung Cancer
-
2022-502584-38-00
5
2023-12-12
Locally advanced squamous cell carcinoma of the head and neck
-
2023-503270-20-00
3
2023-11-29
recurrent or metastatic Adenoid Cystic Carcinoma of the Head and Neck
-
2022-502372-22-01
4
2023-10-19
Metastatic Breast Cancer HR+, HER2-
-
2022-500079-30-00
5
2022-11-03
IgA Nephropathy
-
2022-502392-37-00
4
2022-05-25
elderly patients (> = 60 years) with Acute Myeloid Leukemia
-
2023-506074-12-00
5
2022-03-22
Metastatic Non-Small Cell Lung Cancer
-
2024-515039-31-00
4
2022-02-10
Isatuximab in type I cryoglobulinaemia: A prospective pilot study
-
2023-505457-40-00
5
2022-02-02
Previously Untreated Advanced Gastric or Gastroesophageal Junction
Can